Your browser does not support JavaScript!

Santé humaine biotechnologies domaine d'application

505 entreprises et organismes intervenants dans le domaine 'Santé humaine', classés par activité.

Rejoignez la communauté
Trouvez du matériel
PFIZER
est cité dans une actualité de Labiotech.eu
Il y a 2 semaines
Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline
Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen is a global biotechnology company that discovers, develops and...
www.labiotech.eu
SANOFI AVENTIS
est cité dans une actualité de Labiotech.eu
Il y a 2 semaines
Sanofi adds diabetes drug through Provention Bio $2.9B acquisition
Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered...
www.labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Le 28/12/2022
Merck and Kelun-Biotech collaborating on seven ADC cancer candidates 
Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to...
www.labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Le 28/12/2022
Mersana Therapeutics and Merck to develop novel ADCs
Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug...
www.labiotech.eu
SANOFI AVENTIS
est cité dans une actualité de Labiotech.eu
Le 07/11/2022
Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved
A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants was approved today (November...
www.labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Le 27/09/2022
TILT and MSD working on immunotherapy trial for non-small cell lung cancer
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck...
www.labiotech.eu
SANOFI AVENTIS
est cité dans une actualité de Labiotech.eu
Le 06/09/2022
Sanofi’s Dupixent shows sustained improvement in lung function in children
A maintenance therapy from Sanofi, added to other asthma medications, has shown sustained improvement in lung function, low-rate of asthma attacks and a consistent safety profile for up to two years...
www.labiotech.eu
PFIZER
est cité dans une actualité de Labiotech.eu
Le 29/08/2022
Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology”
Moderna is today (August 26) filing patent infringement lawsuits against Pfizer and its partner BioNTech in both the U.S and Germany. The mRNA-focused biotech claims the companies’ Covid-19 vaccine...
www.labiotech.eu
LILLY FRANCE
est cité dans une actualité de Labiotech.eu
Le 30/05/2022
Up to 500 new jobs as Lilly invests $2.1B in new manufacturing sites
Eli Lilly and Company is boosting its manufacturing footprint by investing $2.1 billion in two new U.S. sites. The new facilities are located at Indiana’s LEAP Lebanon Innovation and Research District...
www.labiotech.eu
PFIZER
est cité dans une actualité de FierceBiotech
Le 20/05/2022
Pfizer teams up with Headlands Research to launch trial sites in more diverse areas
Pfizer teams up with Headlands Research to launch trial sites in more diverse areas gmasson Thu, 05/19/2022 - 10:38...
www.fiercebiotech.com
Charger plus d'actualités